MOTS-c

What is MOTS-c?

MOTS-c is a peptide encoded within the mitochondrial genome — making it one of the few known mitochondria-derived peptides (MDPs). Discovered in 2015, it has been shown to regulate metabolic homeostasis, improve insulin sensitivity, and has been called an 'exercise mimetic' because it activates some of the same metabolic pathways as physical exercise. Human observational studies show circulating MOTS-c levels correlate with insulin sensitivity, obesity, and cardiovascular risk.

What MOTS-c Is Investigated For

MOTS-c is investigated as a mitochondria-derived peptide for metabolic regulation, insulin sensitivity, and as a candidate 'exercise mimetic' acting through AMPK activation — the same energy-sensing pathway engaged by exercise and metformin. The strongest evidence sits in two distinct places: mechanistic preclinical work (AMPK activation via folate-methionine cycle modulation, nuclear translocation under metabolic stress, demonstrated metabolic benefits in rodent obesity and insulin-resistance models), and human observational data linking endogenous circulating MOTS-c levels to insulin sensitivity, obesity, PCOS, cardiovascular risk, and mortality in hemodialysis patients. What is essentially absent is interventional human data: no completed Phase 2 trials of exogenous MOTS-c for any indication, no human pharmacokinetics, and no dose-ranging work. The gap between 'interesting mitochondrial biology with real observational correlates' and 'therapeutic product' is wide — and crucially, whether raising MOTS-c through injection reproduces the protective associations seen with endogenous levels has not been tested. MOTS-c does not replace exercise, research-chemical supply is of unverified purity, and the mitochondrial-to-nuclear translocation that drives much of the interesting biology may not be recapitulated by subcutaneous dosing at all.

History & Discovery

MOTS-c was first described in 2015 by a team led by Pinchas Cohen and Changhan Lee at the University of Southern California. The discovery was conceptually unusual: the peptide is encoded within a small open reading frame embedded inside the mitochondrial 12S ribosomal RNA gene, making it one of the first members of a category of mitochondria-derived peptides (MDPs) — short peptides whose genes sit within mitochondrial DNA rather than the nuclear genome. Humanin, also from the Cohen lab, was the prototype MDP a decade earlier; MOTS-c extended the concept to a metabolically active peptide. The initial paper showed MOTS-c levels rise after acute exercise in humans and that exogenous administration in mice improved insulin sensitivity, reduced obesity on high-fat diet, and engaged AMPK signaling. The 'mitochondrial exercise mimetic' framing followed quickly. Subsequent work extended the biology into muscle, cardiovascular, bone, and brain contexts and identified a mitochondrial DNA polymorphism in the MOTS-c coding region associated with type 2 diabetes risk in certain Asian populations. Despite the scientific traction, MOTS-c has not entered late-stage clinical development; what is sold to consumers under the MOTS-c label is research-chemical synthetic peptide produced outside the regulated pharmaceutical supply chain, with no FDA-approved therapeutic indication.

How It Works

MOTS-c activates AMPK, the same energy-sensing pathway that exercise turns on. This pathway helps cells use glucose more efficiently, improves insulin sensitivity, and activates metabolic processes associated with cellular health and longevity.

MOTS-c activates AMPK (5' AMP-activated protein kinase) through inhibition of the folate-methionine cycle, leading to accumulation of AICAR, an endogenous AMPK activator. This promotes glucose uptake, fatty acid oxidation, and mitochondrial biogenesis. It also translocates to the nucleus during metabolic stress, where it regulates gene expression related to antioxidant response and metabolic adaptation. A 2026 Free Radical Biology and Medicine paper (Gudiksen et al.) extended the muscle-specific picture, showing that MOTS-c improves intrinsic skeletal-muscle mitochondrial bioenergetic health and efficiency in a PGC-1α / AMPK-dependent manner — directly tying the peptide's metabolic effect in muscle to the canonical mitochondrial-biogenesis transcriptional coactivator.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about MOTS-c:

• 01Human pharmacokinetics — absorption, distribution, half-life, and tissue uptake of exogenous MOTS-c have not been characterized in humans.
• 02Dose-ranging in humans — no controlled trial has identified minimum effective or maximum tolerated human doses.
• 03Long-term safety — chronic AMPK activation by exogenous MOTS-c has not been studied beyond short animal windows.
• 04Translation of observational signals — observational human studies link circulating MOTS-c levels to insulin sensitivity, mortality in dialysis patients, and cardiovascular risk, but it is unclear whether raising MOTS-c through exogenous dosing reproduces the protective associations seen with endogenous levels.
• 05Tissue specificity of injected peptide — endogenous MOTS-c is produced within mitochondria and acts in part through nuclear translocation; whether subcutaneous synthetic MOTS-c reaches the relevant intracellular compartments is unresolved.
• 06Reproducibility outside the originating research program — much of the foundational biology comes from one collaborative network; broader independent replication would strengthen confidence.

Forms & Administration

MOTS-c is administered via subcutaneous injection in research contexts. No established clinical protocols exist. All injectable peptides should only be administered under the guidance of a qualified healthcare provider. Never self-administer without clinician oversight.

Dosing & Protocols

The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.

MOTS-c is not FDA-approved for any indication. The numbers above reflect what is described in research literature and online protocols, not a clinical recommendation.

Timeline of Effects

Monitoring & Measurement

Common Questions

Who MOTS-c Is NOT For

Drug & Supplement Interactions

There are no documented human drug-interaction data for MOTS-c because human pharmacology has not been characterized. The following are theoretical and derived from mechanism. The most plausible practical interaction is with antidiabetic medications. MOTS-c activates AMPK and improves insulin sensitivity, so additive effects with insulin, sulfonylureas, meglitinides, and metformin (which independently activates AMPK) are theoretically possible. Hypoglycemia monitoring would be appropriate in any insulin-treated patient considering MOTS-c. Because MOTS-c modulates the folate-methionine cycle on its way to AMPK activation, theoretical interactions exist with methotrexate and other antifolate drugs, though magnitude is unstudied. Co-administration with other AMPK-active compounds (metformin, AICAR, berberine) may produce additive but uncharacterized metabolic effects. Patients on any chronic medication should disclose MOTS-c use to their clinicians.

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions